SCHOLAR ROCK HOLDING CORP (SRRK)

Company Profile

Scholar Rock Holding Corp. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 150 full-time employees. The company went IPO on 2018-05-24. The firm is focused on the discovery, development and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled the Company to develop a proprietary platform for the development of monoclonal antibodies that locally and selectively target the precursor. Its product candidate, apitegromab, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as the first muscle-targeted therapy for the treatment of spinal muscular atrophy (SMA). Its other product candidate, SRK-181, a selective inhibitor of the activation of latent TGFb, is being developed for the treatment of cancers.

Company Info

SCHOLAR ROCK HOLDING CORP

301 Binney Street, 3rd Floor

Cambridge MASSACHUSETTS 02142

P: 18572593860

CEO: Stuart A. Kingsley

Employees: 150

Website: https://scholarrock.com/